##1. Classic Model of Iron Metabolism and Unexplained Gaps The prevailing biological paradigm held that, under stress conditions such as anemia or hemorrhage, erythroid progenitor cells in the bone marrow secrete erythroferrone (ERFE), which suppresses hepatic hepcidin to increase iron availability. However, in actual stress erythropoiesis, a rapid iron mobilization mechanism exists that cannot be explained solely by erythroid signals, representing a longstanding challenge in the field.

##2. Osteoblasts: A Novel Endocrine Organ Directing Hematopoiesis Using mouse models and tissue‑specific genetic manipulation, the investigators demonstrated for the first time that osteoblasts, the bone‑forming cells, become the principal source of ERFE during stress. Osteoblast‑derived ERFE directly sequesters bone morphogenetic proteins (BMPs), thereby potently inhibiting hepcidin activity. This suggests that bone functions not merely as a structural scaffold but as an active regulatory organ that rapidly reallocates systemic iron to support hematopoiesis.

##3. ERFE‑BMP Pathway: Central Engine for Acute Anemia Recovery The causal relationship between osteoblast‑derived ERFE and BMP elucidates a ‘ultra‑rapid’ mechanism by which the organism responds to sudden blood loss. By blocking BMP signaling, osteoblasts suppress hepatic hepcidin production, leading to a dramatic increase in intestinal iron absorption and the release of stored iron. Consequently, the body can swiftly regenerate erythrocytes after life‑threatening hemorrhage, restoring oxygen‑delivery capacity as a survival strategy.

##4. The Dawn of Skeletal‑Hematologic Integrated Therapy and Its Clinical Significance This work shifts the paradigm of anemia therapy from a purely hematopoietic focus to one centered on skeletal‑hematologic interaction. By identifying the osteoblast‑ERFE axis as a novel therapeutic target, it offers a breakthrough for patients with refractory, idiopathic anemia who have failed conventional treatments. The findings provide decisive scientific justification for delivering integrated precision‑medicine solutions to elderly individuals who concurrently suffer from skeletal disorders such as osteoporosis and anemia.